Published on
Associate Dean and Professor Erika Lietzan‘s new article forthcoming in the SMU Law Review, “FDA After Loper Bright,” was recently reviewed in “The Regulatory Review.”
The Review article highlights Professor Lietzans argument that the Loper Bright decision “may not be nearly as devastating” for the U.S. Food and Drug Administration (FDA) as many scholars believe it will be.